The Xyrem(®) (Sodium Oxybate) Risk Evaluation and Mitigation Strategy (REMS) Program in the USA: Results From 2016 to 2017

BACKGROUND: Sodium oxybate, which is approved for the treatment of cataplexy or excessive daytime sleepiness in patients with narcolepsy, is available in the USA only through the restricted-distribution Xyrem(®) Risk Evaluation and Mitigation Strategy Program (Xyrem REMS Program, XRP). The XRP requi...

Descripción completa

Detalles Bibliográficos
Autores principales: Strunc, Michael J., Black, Jed, Lillaney, Prasheel, Profant, Judi, Mills, Sherice, Bujanover, Shay, Thorpy, Michael J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7984153/
https://www.ncbi.nlm.nih.gov/pubmed/33439474
http://dx.doi.org/10.1007/s40801-020-00223-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7984153/
https://www.ncbi.nlm.nih.gov/pubmed/33439474
http://dx.doi.org/10.1007/s40801-020-00223-6

Ejemplares similares